Melodiol Global Health (ASX:ME1DA) Debt-to-Equity : -2.38 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Melodiol Global Health Debt-to-Equity?

Melodiol Global Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$9.56 Mil. Melodiol Global Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.08 Mil. Melodiol Global Health's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$-4.06 Mil. Melodiol Global Health's debt to equity for the quarter that ended in Dec. 2023 was -2.38.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Melodiol Global Health's Debt-to-Equity or its related term are showing as below:

ASX:ME1DA' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.38 Med: 0.18 Max: 0.3
Current: -2.38

During the past 8 years, the highest Debt-to-Equity Ratio of Melodiol Global Health was 0.30. The lowest was -2.38. And the median was 0.18.

ASX:ME1DA's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs ASX:ME1DA: -2.38

Melodiol Global Health Debt-to-Equity Historical Data

The historical data trend for Melodiol Global Health's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Melodiol Global Health Debt-to-Equity Chart

Melodiol Global Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.18

0.24

0.30

-2.38

Melodiol Global Health Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial										-	-	0.30	1.21	-2.38

Competitive Comparison of Melodiol Global Health's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Melodiol Global Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Melodiol Global Health's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Melodiol Global Health's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Melodiol Global Health's Debt-to-Equity falls into.

Melodiol Global Health Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Melodiol Global Health's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.562	+	0.084)	/	-4.058
	=	-2.38

Melodiol Global Health's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.562	+	0.084)	/	-4.058
	=	-2.38

Melodiol Global Health (ASX:ME1DA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Melodiol Global Health Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Melodiol Global Health's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Melodiol Global Health (ASX:ME1DA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Melodiol Global Health Ltd (ASX:ME1DA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

COPHF:USA

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.cresopharma.com

Melodiol Global Health Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its brands include Mernova: A licensed producer of cannabis products in Canada for sale under the Ritual brand banner. Sierra Sage Herbs: US-based developer of plant-based, beauty, and personal care brands Green Goo, Southern Butter, and Good Goo. impACTIVE: CBD topical products for athletes. Halucenex: Clinical stage psychedelics research and development operation. Creso Pharma Switzerland: CBD-related research, development, and commercialization.

Melodiol Global Health (ASX:ME1DA) Headlines

No Headlines